The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Are we sleepwalking into AI disruption in GI?
- AI Digital Twins Are Helping People Manage Diabetes and Obesity (WIRED)
- 3 Healthcare Threats That Will Soon Become Too Big To Solve (Forbes)
- From GLP-1s to engineered probiotics: New research highlights evolving IBD care (AGA)
- Physician consolidation squeeze: Rising costs and tight cash flow are reshaping practice growth (Physicians Practice)
- The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health (Nature Reviews Gastroenterology & Hepatology)
- Medical Malpractice: Staying Out of Trouble (GI & Endoscopy News)
- Evaluating Benefits of AI During Colonoscopy (GI & Endoscopy News)
